Netherlands-based immuno-oncology company Merus and the Institute for Research in Biomedicine (IRB) Barcelona have collaborated to jointly develop novel agents that target the tumour microenvironment.

Under the research collaboration, Merus’ Biclonics technology platform for the discovery and development of therapeutic bispecific antibodies will be combined with IRB’s cell and animal models to evaluate therapeutic targeting of stromal cells.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Merus chief scientific officer Mark Throsby said: “This new research collaboration builds on the successful working relationship established in the suppresSTEM consortium that resulted in MCLA-158, a Biclonics targeting EGFR and Lgr5 that is currently in IND-enabling studies.

“We anticipate that accessing IRB’s insights and tools to investigate the tumour stromal environment will support the discovery and validation of Biclonics that block the initiation and progression of metastatic cancer.”

“We are optimistic that this partnership will streamline the generation of differentiated therapeutics to treat patients with difficult-to-treat cancer subtypes.”

Founded in October 2005 by the Government of Catalonia and the University of Barcelona, the IRB research centre is devoted to understanding fundamental questions about human health and disease. It is located at the Barcelona Science Park.

IRB professor and group leader Eduardo Battle said: “Merus’ Biclonics technology represents a promising platform to develop bispecific antibodies to specifically target the tumour stroma.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are optimistic that this partnership will streamline the generation of differentiated therapeutics to treat patients with difficult-to-treat cancer subtypes.”

Merus develops human bispecific antibody therapeutics known as Biclonics, based on the full-length IgG format.